anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: complex processing apiculture products and seafoods. SUBSTANCE: treatment-and-prophylactic preparation VINIBIS-M contains beebread and powder of microcrystalline cellulose. Product desiccation is conducted in vacuum chamber at temperature not more 45 C and pressure not more 100 esiccation of product in vacuum chamber, preliminary desiccation of raw material is carried out by convection up to 15% humidity. Then raw material is decontaminated, cooled and beebread is recovered at temperature 0-5 C. After it, product is mixed with powder of microcrystalline cellulose and ground up to obtaining homogeneous powder. Method allows to obtain ecological clean treatment-and-prophylactic product with maximum conservation of biological properties. EFFECT: increased efficiency, productive capacity and safety of method. 1 dwg
PROBLEM TO BE SOLVED: To obtain talc having low oil absorbing property and suppressing discoloration due to oil absorption at the time of use in cosmetics and to obtain cosmetics less liable to discoloration at the time of use by adding iron oxide and iron hydroxide to talc and carrying out heat treatment in a specified temp. range. SOLUTION: A mixture of talc with iron oxide and/or iron hydroxide is heat-treated at 800-1,500 deg.C. By this heat treatment, the high oil absorbing property of the talc is varied and the objective modified talc having low oil absorbing property is obtd. Cosmetics contg. the modified talc especially in combination with a coloring pigment are less liable to absorb secretions, etc., from the skin at the time of use and are less liable to discoloration. The weight ratio between talc and iron oxide and/or iron hydroxide in the mixture is about 98:2 to 99.99:0.01.
Drugs may interact with COUMADIN through pharmacodynamic or pharmacokinetic mechanisms. Pharmacodynamic mechanisms for drug interactions with COUMADIN are synergism (impaired hemostasis, reduced clotting factor synthesis), competitive antagonism (vitamin K), and alteration of the physiologic control loop for vitamin K metabolism (hereditary resistance). Pharmacokinetic mechanisms for drug interactions with COUMADIN are mainly enzyme induction, enzyme inhibition, and reduced plasma protein binding. It is important to note that some drugs may interact by more than one mechanism.

More frequent INR monitoring should be performed when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs, including drugs intended for short-term use (e.g., antibiotics, antifungals, corticosteroids) [see Boxed Warning].

Consult the labeling of all concurrently used drugs to obtain further information about interactions with COUMADIN or adverse reactions pertaining to bleeding.
A total of 250 participants, who are physiotherapy and rehabilitation intern students in Turkey, will be included in the present study. Data collection will be carried out using an online survey. The online survey link will be shared via social media accounts and via mail. The questionnaire created through Google forms will be delivered to the participants via the link. The link will be active in the data collection process. Before the participants start the questionnaire, they will be asked whether they were willing to participate. The socio-demographic characteristics (age, gender, weight, height) and health status (presence of chronic disease and drugs used) will be questioned. In addition, the information about the institution where the internship was held and the duration of the internship, internship hours, time spent at the internship will be collected. Personal Protective Equipment Comfort and User Attitude Evaluation Form will be used to evaluate participant's thoughts, attitudes and behaviors towards the use of personal equipment also physical complaints, comfort level due to personal protective equipment.
The description of the experimental design followed the Consolidated Standards of Reporting Trials (CONSORT) statement. The present study was a double-blinded (patients and examiner) randomized clinical trial anticipating the split mouth design. Thirty-five adult patients seeking dental treatment in Operative Department clinic at Faculty of Dentistry, University of Mansoura were enrolled in the current study with a total of 70 Class I restorations. No advertisement was made for participant recruitment, forming a sample of convenience. Each patient much sign a consent form before participating in the current study. The study was conducted from October 2017 to June 2020 as a part of Doctoral dissertation. Mansoura University institution's ethics committee approved the form and protocol before conducting the study. The sample size was calculated based on the clinical success rate (100% retention rate at 3 years) of posterior class I restorations restored with nanofilled composite observed in a previous study.28 According to several parameters including a significance level of 5%, the power of the test was calculated to be 80%, and equivalent limit of 15%. Upon these data, a sample size of 30 subjects was appropriate. Allowing for a 20% drop-out, sample size was set totalizing 35 subjects.
The objective of this study was to establish a nausea-free ward model and evaluate the effect of an intervention procedure guided by this model on chemotherapy-induced nausea and vomiting (CINV) in cancer patients. A total of 105 chemotherapy patients from March to September 2022 before the establishment of nausea-free ward in the Chongqing Jiulongpo District People's Hospital were selected as the control group as well as 105 chemotherapy patients from March to September 2023 after the establishment of nausea-free ward as the intervention group. The intervention group was managed by comprehensive standardized CINV management on the basis of the control group. Finally, the Chinese Society of Clinical Oncology grading tool for nausea and vomiting and the Functional Living Index-Emesis were used to evaluate the effect. Under the intervention of the nausea-free ward model, the intervention group exhibited significantly lower ratings of nausea and vomiting compared to the control group (all P-value <.05). The nausea score, vomiting score, and total score of the intervention group were significantly lower than the control group (all P-value <.05). Our study found CINV symptoms and quality of life can be significantly improved by the application of the nausea-free ward model. The nausea-free ward model is instructive in clinical practice and can guide clinical work as well as bring management experience to clinical workers.
Tumor lysis syndrome has been reported in CLL patients treated with Fludarabine Phosphate for Injection. This complication may include hyperuricemia, hyperphosphatemia, hypocalcemia, metabolic acidosis, hyperkalemia, hematuria, urate crystalluria, and renal failure. The onset of this syndrome may be heralded by flank pain and hematuria.

Nervous System (see WARNINGS section)

Objective weakness, agitation, confusion, seizures, visual disturbances, optic neuritis, optic neuropathy, blindness and coma have occurred in CLL patients treated with Fludarabine Phosphate for Injection at the recommended dose. Peripheral neuropathy has been observed in patients treated with Fludarabine Phosphate for Injection and one case of wrist-drop was reported. There have been additional reports of cerebral hemorrhage though the frequency is not known.
Lamivudine or emtricitabine are commonly used in combination with other drugs for first-line treatment of HIV infection. Although effective initially, many people later on develop resistance to some or all of the drugs (including lamivudine) leading to virological failure. Resistance is associated with characteristic mutations, which for lamivudine is the M184V mutation. A change to new, active drugs must take place when patients fail their current regime, to regain control of the virus. Although there are other types of drugs available for second line treatment, there is currently no fully active, well tolerated cytidine analogue that can replace lamivudine in a second-line regimen when patients fail first line treatment. This study will measure the efficacy and safety of AVX754 (a novel cytidine analogue with activity against HIV resistant to other nucleosides) as part of a new regimen to treat patients who have failed treatment containing lamivudine, compared to the best alternative new regimen which continues to include lamivudine.
Despite the early recognition of obesity as an epidemic with global implications, research on its pathogenesis and therapeutic approach is still on the rise. The literature of the 21st century records an excess weight found in up to 1/3 of children. Both the determining factors and its systemic effects are multiple and variable. Regarding its involvement in the potentiation of cardio-vascular, pulmonary, digestive, metabolic, neuro-psychic or even dermatological diseases, the information is already broadly outlined. The connection between the underlying disease and the associated comorbidities seems to be partially attributable to oxidative stress. In addition to these, and in the light of the recent COVID-19 pandemic, the role played by oxidative stress in the induction, maintenance and potentiation of chronic inflammation among overweight children and adolescents becomes a topic of interest again. Thus, this review's purpose is to update general data on obesity, with an emphasis on the physiopathological mechanisms that underlie it and involve oxidative stress. At the same time, we briefly present the latest principles of pathology diagnosis and management. Among these, we will mainly emphasize the impact played by endogenous and exogenous antioxidants in the evolutionary course of pediatric obesity. In order to achieve our objectives, we will refer to the most recent studies published in the specialized literature.
BACKGROUND: Neonatal sepsis is one of the most common causes of disease and death among neonates globally. And it made a great contribution to neonatal admission to intensive care units. To mitigate the ongoing neonatal crisis and accomplish the goal of sustainable development through a decrease in neonatal mortality, information from various regions is needed. Despite the considerable burden of neonatal sepsis in our setting, no prior studies were conducted in the study area. So, this study aimed to assess the magnitude and associated factors of neonatal sepsis among neonates admitted to the neonatal intensive care unit at Hawassa University Comprehensive Specialized Hospital, Sidama Regional State, Ethiopia.
METHODS: A hospital-based cross-sectional study was carried out among 287 neonates from March 1, 2020, to April 25, 2020. An interviewer-administered structured questionnaire was used to collect the data. The data were cleaned, coded, and entered into Epi Data 3.1 software and exported to Statistical Package for Social Science (SPSS) software version 23.0 for analysis. Binary logistic regression analyses were performed to identify variables having a significant association with neonatal sepsis. A p-value of ≤ 0.05 was considered statistically significant during multivariable logistic regression.
RESULTS: The study found that the magnitude of neonatal sepsis was 56%. The mean age of neonates was 3.2(SD±2.2) days. Around two-fifths (39%) of neonates were in the gestational age of <37 completed weeks. A quarter of mothers(25.8%) were delivered through cesarean section. During labor, 251 (87.5%) mothers had ≤4 digital vaginal examinations. Moreover, the finding revealed that mothers who delivered by cesarean section [AOR = 2.13, 95% CI (1.090-4.163)]. neonates who had been resuscitated at birth [AOR = 4.5, 95% CI (2.083-9.707)], and neonates who had NG tube inserted [AOR = 4.29, 95% CI (2.302-8.004)] were found to be significantly associated with neonatal sepsis.
CONCLUSIONS: The current study shows that neonatal sepsis was prevalent among more than half of the neonates admitted to the NICU. Therefore, designing strategies to enhance the aseptic techniques of professionals in the provision of care and actively and collaboratively working with cluster health facilities is highly recommended.
1. Process for preparing inhalable powders, characterised in that N+m substantially equal portions of a substance having a larger particle size distribution (excipient) and N equal portions of a substance having a smaller particle size distribution (active substance) are placed in alternate layers in a suitable mixing vessel and after they have all been added the 2N+m layers of the two components are mixed together using a suitable mixer, a portion of the substance having the larger particle size being put in first, while N is an integer >0, preferably >5, and m denotes 0 or 1. 2. Process according to claim 1, characterised in that the individual fractions are added in layers through a suitable screening apparatus. 3. Process according to claim 1 or 2, characterised in that m denotes the number 1. 4. Process according to one of claims 1, 2 or 3, characterised in that inhalable powders are obtained containing less than 5%, preferably less than 2% of active substance. 5. Process according to one of claims 1 to 4, characterised in that the active substance used has a particle size of from 0.5 to 10 mum, preferably from 1 to 6 mum. 6. Process according to one of claims 1 to 5, characterised in that the excipient used has a mean particle size of from 10 to 100 mum, preferably 15 to 80 mum. 7. Process according to one of claims 1 to 5, characterised in that the excipient consists of a mixture of coarser excipient with an average particle size of 15 to the proportion of finer excipient constituting 1 to 20% of the total amount of excipient. 8. Process according to one of claims 1 to 7, characterised in that the active substance present consists of one or more compounds selected from among the betamimetics, anticholinergics, corticosteroids and dopamine agonists. 9. Inhalable powder obtainable by a process according to one of claims 1 to 8.
The goals of this study are to: 1) demonstrate the efficacy of Recovering Together for improving self-reported emotional distress (primary outcome), and post traumatic stress, mindfulness, coping, social support and other relevant outcomes (secondary outcomes); and 2) assess mechanisms (mediators and moderators) of improvement after intervention. We will enroll and randomly assign 194 at risk dyads (97 per study group) to receive either the active intervention or educational control. The trial is single blinded (assessors, patients and staff). The trial will take place at the Massachusetts General Hospital NICU using our established methodology successfully implemented during the R21 pilot study. Study clinicians will deliver 6, 30 minute sessions of active intervention or educational control (2 at bedside and 4 via live video after discharge) to each patient-caregiver dyad. All participants will complete measures at baseline, after completion of program (6 weeks) and 3 months later. They will also complete measures of emotional distress weekly, as well as measures assessing home practice.
A computer-implemented method of planning orthopaedic surgery comprises providing a library of templates representing orthopaedic prostheses, displaying and scaling one or more patient images such as X-ray images, allowing a user to reconfigure geometrical constructs displayed over the images to match the construct to anatomical features shown in the image; and selecting one or more templates from the library in accordance with parameters of the reconfigured constructs. The templates correspond to the orthopaedic prosthesis or prostheses which are most suitable for the patient. Hip replacement surgery can be planned using a single patient image. Knee surgery can be planned using two patient images showing different views of the anatomical features, in which case geometrical constructs for use with each view are provided. The library of templates is accessible via the Internet so as to be accessible by users in any location and readily updateable. <IMAGE>
Administer QVAR by the orally inhaled route in patients 5 years of age and older. QVAR does not require shaking prior to use. After inhalation, the patient should rinse his/her mouth with water without swallowing to help reduce the risk of oropharyngeal candidiasis. 

Use of QVAR with a spacer device in children less than 5 years of age is not recommended. [see Use in Specific Populations (8.4)]

Patients should be instructed on the proper use of their inhaler. Consistent dose delivery is achieved, whether using the 40 or 80 mcg strengths, due to proportionality of the 2 products (i.e., 2 actuations of 40 mcg strength should provide a dose comparable to 1 actuation of the 80 mcg strength).

Priming: Patients should prime QVAR by actuating into the air twice before using for the first time or if QVAR has not been used for over 10 days. Avoid spraying in the eyes or face when priming QVAR. 

Dose Counter: QVAR has a dose counter attached to the actuator. When the patient receives the inhaler, a black dot will appear in the viewing window until it has been primed 2 times, at which point the total number of actuations will be displayed. The dose counter will count down each time a spray is released. The dose-counter window displays the number of sprays left in the inhaler in units of two (e.g., 120, 118, 116, etc). When the dose counter reaches 20, the color of the numbers will change to red to remind the patient to contact their pharmacist for a refill of medication or consult their physician for a prescription refill. When the dose counter reaches 0, the background will change to solid red.

Discard QVAR inhaler when the dose counter displays 0 or after the expiration date on the product, whichever comes first.
A formulation and a method for manufacturing an acne extraction patch. Water is added into polyvinyl alcohol and polyvinyl pyrrolidone to form an polymer solution. An adequate excipient is further added to form an optimal formulation. The formulation is coated directly onto the hydrophilic nonwovens or the nonwovens are placed over the release liner after coating the release liner with silicon coating. After the steps described above, the nonwovens are put into the dry oven for a two-step drying method at 55-90° C., and 80-95° C. A die-cut and package machine is used to cut an adequate patch. The patch is moistened with water and applied to the face or nose. The water solution of the formulation penetrates into the hair follicles or sebaceous glands. The lug of acne sticks to the polymer patch as the water evaporates. The acne is extracted from the hair follicle as the patch is removed.
Participants randomized to the flecainide arm will be prescribed a single 300mg dose of oral flecainide, to be given as soon as possible after study randomization. Rate controlling drugs will be prescribed and titrated to achieve a heart rate of less than 100 beats per minute and symptom minimization.
The invention provides noodles with various tastes and long-acting preventive and curative effects on cold, and the preparation method thereof. The invention solves the problems of the noodles, such as single taste and no disease preventive effect. The noodles comprise, by weight parts: 90-100 parts of flour, 1-2.5 parts of flavoring agents and 10-15 parts of medicinal juice. The preparation method of the noodles comprises the steps of: mixing 90-100 parts of the flour, 1-2.5 parts of the flavoring agents and 10-15 parts of the medicinal juice by weight parts, stirring to form the dough and pressing into the noodles. The original drug effect of the medicinal juice is retained. On one hand, the drug durability is reinforced and the drug release time is prolonged due to the protein in the noodles. On the other hand, the drug taste is overwhelmed by using the flavoring agent. The noodles have the advantages of various tastes, abundant nutrition, long shelf life, and convenient transportation and processing, and stimulate the appetite.
Disclosed are methods of enhancing respiratory syncytial virus (RSV) immunity in a human subject. The methods encompass administering to a subject a single intramuscular dose of a composition comprising about 20 μg, about 50 μg, 80 μg or about 120 μg RSV soluble F protein. The composition further contains an adjuvant of glucopyranosyl lipid A (GLA) in a squalene-based stable emulsion. The RSV soluble F (sF) protein is amino acids 1-524 of RSV soluble F protein from human strain A2 lacking a transmembrane domain (SEQ ID NO: 1). In some embodiments the subject is human and is at least about 60 years old, or between at least about 60 years old and about 87 years old. In additional embodiments, the method of enhancing RSV immunity in the subject results in enhancing a Th1 biased cellular immune response in the subject, inducing neutralizing antibodies against RSV in the subject, reducing RSV viral titers in the subject, inducing an immune response to RSV in the subject, and/or preventing RSV infection in the subject.
Only a third of individuals with mild cognitive impairment (MCI) progress to dementia of the Alzheimer's type (DAT). Identifying biomarkers that distinguish individuals with MCI who will progress to DAT (MCI-Converters) from those who will not (MCI-Non-Converters) remains a key challenge in the field. In our study, we evaluate whether the individual rates of loss of volumes of the Hippocampus and entorhinal cortex (EC) with age in the MCI stage can predict progression to DAT. Using data from 758 MCI patients in the Alzheimer's Disease Neuroimaging Database, we employ Linear Mixed Effects (LME) models to estimate individual trajectories of regional brain volume loss over 12 years on average. Our approach involves three key analyses: (1) mapping age-related volume loss trajectories in MCI-Converters and Non-Converters, (2) using logistic regression to predict progression to DAT based on individual rates of hippocampal and EC volume loss, and (3) examining the relationship between individual estimates of these volumetric changes and cognitive decline across different cognitive functions-episodic memory, visuospatial processing, and executive function. We find that the loss of Hippocampal volume is significantly more rapid in MCI-Converters than Non-Converters, but find no such difference in EC volumes. We also find that the rate of hippocampal volume loss in the MCI stage is a significant predictor of conversion to DAT, while the rate of volume loss in the EC and other additional regions is not. Finally, individual estimates of rates of regional volume loss in both the Hippocampus and EC, and other additional regions, correlate strongly with individual rates of cognitive decline. Across all analyses, we find significant individual variation in the initial volumes and the rates of changes in volume with age in individuals with MCI. This study highlights the importance of personalized approaches in predicting AD progression, offering insights for future research and intervention strategies.
The use of telehealth in pulmonary rehabilitation, also known as telerehabilitation, is a novel approach in healthcare practice. In order to effectively implement telerehabilitation programs, it is important to evaluate how potential users perceive and accept this new type of program. Thus, the aim of this research was to create a measuring tool that could assess the level of acceptance of telerehabilitation among healthcare providers and patients. A group of experts in pulmonary rehabilitation, telehealth, information technology, and scale development have reviewed and confirmed the content validity of the Tele-Pulmonary Rehabilitation Acceptance Scale. This scale is significant because it offers a consistent means of collecting data to measure the level of acceptance towards telerehabilitation among potential users. This study aims to translate and show the consistency and validity of the Tele-Pulmonary Rehabilitation Acceptance Scale in Turkish.